Exploring the 24h-effect of targeted therapies in non-small cell lung cancer from exon array blood profiling using dually constrained correspondence analysis

Florent Baty (St. Gallen, Switzerland), Florent Baty, Martin Brutsche

Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Session: Lung cancer: prognostic factors and features of oncogene-driven tumours
Session type: Thematic Poster Session
Number: 4239
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Florent Baty (St. Gallen, Switzerland), Florent Baty, Martin Brutsche. Exploring the 24h-effect of targeted therapies in non-small cell lung cancer from exon array blood profiling using dually constrained correspondence analysis. Eur Respir J 2015; 46: Suppl. 59, 4239

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
High-throughput detection of alternative splicing in patients with non-small cell lung cancer treated by bevacizumab/erlotinib
Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer
Year: 2014


Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014


Metabolic modification as a potential therapeutics approach in lung cancer
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013


Large-scale quantitative proteomic analysis identifies pathways in COPD-associated lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015


Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015


Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016


Exploiting metabolomic approaches to aid in the diagnosis of lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016

A tissue microarray analysis on the role of chromosome 7 multiplication regarding the EGFR expression in non-small cell lung carcinomas
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016

Determining genomic rearrangements in clinical lung specimens for assessment of metastatic disease, actionable targets and disease monitoring
Source: International Congress 2016 – New genomic targets in pulmonary disease
Year: 2016


DNA methylation profiling of non-small cell lung cancer reveals an immune signature in COPD patients
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013


Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013

Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014

Telomere-associated gene network in lung adenocarcinoma
Source: International Congress 2015 – Respiratory translational research: novel mechanisms, diagnostic markers and Space Odyssey
Year: 2015



Optimization of cfDNA routine use for NSCLC genomic alteration analysis
Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease
Year: 2016


Circulating biomarkers and tumour molecular profiling in patients with non-small cell lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015

Tumor-associated stromal gene expression signatures predict therapeutic response to erlotinib/bevacizumab in non-small cell lung cancer (NSCLC)
Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases
Year: 2014

Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016

The utility of bronchoscopically acquired tissue for successful lung cancer molecular profiling (LC-MP)
Source: Annual Congress 2013 –Comfort, safety and effectiveness of bronchoscopy
Year: 2013


Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014

Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015